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Abstract
Background: Non-pharmacological treatment options for hypertension have the potential to
reduce the risk of cardiovascular disease at a population level. Animal studies have suggested that
garlic reduces blood pressure, but primary studies in humans and non-systematic reviews have
reported mixed results. With interest in complementary medicine for hypertension increasing, it
is timely to update a systematic review and meta-analysis from 1994 of studies investigating the
effect of garlic preparations on blood pressure.
Methods: We searched the Medline and Embase databases for studies published between 1955
and October 2007. Randomised controlled trials with true placebo groups, using garlic-only
preparations, and reporting mean systolic and/or diastolic blood pressure (SBP/DBP) and standard
deviations were included in the meta-analysis. We also conducted subgroup meta-analysis by
baseline blood pressure (hypertensive/normotensive), for the first time. Meta-regression analysis
was performed to test the associations between blood pressure outcomes and duration of
treatment, dosage, and blood pressure at start of treatment.
Results: Eleven of 25 studies included in the systematic review were suitable for meta-analysis.
Meta-analysis of all studies showed a mean decrease of 4.6 ± 2.8 mm Hg for SBP in the garlic group
compared to placebo (n = 10; p = 0.001), while the mean decrease in the hypertensive subgroup
was 8.4 ± 2.8 mm Hg for SBP (n = 4; p < 0.001), and 7.3 ± 1.5 mm Hg for DBP (n = 3; p < 0.001).
Regression analysis revealed a significant association between blood pressure at the start of the
intervention and the level of blood pressure reduction (SBP: R = 0.057; p = 0.03; DBP: R = -0.315;
p = 0.02).
Conclusion:  Our meta-analysis suggests that garlic preparations are superior to placebo in
reducing blood pressure in individuals with hypertension.
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Background
Hypertension (systolic blood pressure (SBP) ≥ 140 mm
Hg; diastolic blood pressure (DBP) ≥ 90 mm Hg) is a
known risk factor for cardiovascular morbidity and mor-
tality, affecting an estimated 1 billion individuals world-
wide [1]. Recently updated guidelines for the treatment of
high blood pressure stress the importance of preventive
strategies, and recommend extending the management of
blood pressure to include pre-hypertensive individuals
(SBP 120–139/DBP 80–89 mm Hg) [1]. Primary manage-
ment should include relevant lifestyle modifications such
as increased exercise, weight loss and dietary changes
which could incorporate dietary supplementation.
Garlic (Allium sativum) has played an important dietary as
well as medicinal role in human history [2]. Blood pres-
sure reducing properties of garlic have been linked to its
hydrogen sulphide production [3] and allicin content –
liberated from alliin and the enzyme alliinase [4,5] –
which has angiotensin II inhibiting and vasodilating
effects, as shown in animal and human cell studies [3,6-
10].
Primary studies in humans and reviews of garlic prepara-
tions and blood pressure have been inconclusive [11-40].
A meta-analysis published in 1994 reported promising
results in subjects with mild hypertension but found
insufficient evidence to recommend garlic for clinical
therapy [41]. The increasing use of alternative and com-
plementary therapies for hypertension [42,43] makes it
timely to provide an updated systematic review and meta-
analysis of trials investigating the effect of garlic prepara-
tions on blood pressure. Inclusion of additional data from
studies published since 1994 has enabled subgroup meta-
analyses of hypertensive and normotensive subjects.
Methods
Literature search
We searched the Medline, Embase and Cochrane data-
bases for studies published between 1955 and Oct 2007
using the search terms [garlic AND ("blood pressure" OR
hypertens* OR pre-hypertens* OR prehypertens*)] to
identify intervention studies investigating the effect of gar-
lic on blood pressure. We also checked reference lists of
previously published systematic reviews and meta-analy-
ses for additional primary studies [36,41].
Study selection
In the systematic review we included published interven-
tion studies (these included randomised controlled trials
and non-placebo controlled trials), reporting effects of
garlic on blood pressure and published in English or Ger-
man (Table 1 and Additional File 1). Stricter criteria were
required for inclusion in meta-analysis: Only studies with
placebo control groups, using garlic-only supplements,
and reporting mean systolic and/or diastolic blood pres-
sure (SBP/DBP) and standard deviation (SD) were eligible
for meta-analysis (Table 1). We contacted authors of stud-
ies with suitable study design but incomplete published
data (mean SBP/DBP or SD) to retrieve complete data sets
for meta-analysis. Figure 1 summarises the study selection
process.
Data extraction and quality assessment for meta-analysis
The number of subjects in intervention and control
groups, mean SBP and DBP at start and end of interven-
tion and SD were collated from text, tables or figures.
Methodological quality was assessed independently by
two investigators (KR and PF) using guidelines by the
Cochrane Collaboration [44] (Tables 2 and 3), and disa-
greements were resolved by consensus. All studies consid-
ered for meta-analysis (n = 11, Table 2) reported adequate
randomisation and double blinding, and all but one [14]
assessed blood pressure as co-primary outcome measure.
Six of eleven studies reported drop-out rates between 0
and 13% [13,14,17,18,20,21], two studies of less than
22% [15,19], and three studies did not provide details
[11,12,16]. We considered the quality of all eleven studies
as sufficient to be included in meta-analysis.
Data synthesis and meta-analysis
Changes in mean SBP or DBP of garlic and control groups
before and after intervention were entered into the meta-
analysis using Review Manager version 4.2 [45]. Standard
deviations of these differences were estimated applying
the equation published in Taubert et al. [46] and using a
conservative correlation coefficient of R = 0.68 as sug-
gested by the Cochrane Handbook for Systematic Reviews
of Interventions [44]. If heterogeneity was high (I2>50%)
we used the random effects model for meta-analysis, oth-
erwise the fixed effects model was considered appropriate
[47,48].
In addition, we performed subgroup meta-analysis of tri-
als with hypertensive subjects at start of treatment (mean
SBP ≥ 140 mm Hg or mean DBP ≥ 90 mm Hg) and sub-
group analysis of trials with normotensive subjects at start
of treatment (mean SBp < 140 mm Hg or mean DBp < 90
mm Hg).
Potential publication bias in the meta-analysis was
assessed by Begg's funnel plots and Egger's regression test
[49,50].
Meta-regression was performed to find any association
between blood pressure changes over time and the follow-
ing continuous variables: dosage, length of intervention,
and blood pressure at start of treatment. We also tested for
any evidence of confounding related to source of fundingBMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
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Table 1: Characteristics of randomised controlled trials included in meta-analysis examining the effect of garlic on blood pressure
Source Study design; 
Intervention/
control groups
Type of garlic 
preparation, 
Dosage, Duration
Number of 
participants in 
intervention vs 
control group
Mean SBP (SD) at 
start/end of 
intervention vs 
control in mm Hg
Mean DBP (SD) at 
start/end of 
intervention vs 
control in mm Hg
Kandziora J 1988 
(Study 1), [11]
Parallel, Garlic powder (Kwai), 20/20 Garlic: 174 (4)/158 
(10)
Garlic: 99 (3)/83 (4)
Diuretic drug (Dytide 
H) + garlic/drug only
600 mg/d, (standing) Control: 175 (8)/169 
(6)
Control: 98 (5)/90 (3)
12 wks
Auer et al. 1990, [12] Parallel, Kwai, 24/23 Garlic: 171 (21.6)/152 
(19.6)
Garlic: 102 (13)/89 
(4.4)
Garlic/placebo 600 mg/d, Control: 161 (19)/153 
(19)
Control: 97 (12.9)/93 
(10.6)
12 wks
Vorberg & Schneider 
1990, [13]
Parallel, Kwai, 20/20 Garlic: 144.5 (13.4)/
138.5 (4.3)
Garlic: 91 (3.9)/87 
(3.7)
Garlic/placebo 900 mg/d, Control: 144 (10.4)/
147 (7.1)
Control: 88 (6.1)/90 
(3.7)
16 wks
Holzgartner et al. 
1992, [14]
Parallel, Kwai, 47/47 Garlic: 143.4 (15.4)/
135.4 (14.6)
Garlic: 82.8 (10.5)/
78.6 (9.3)
Lipid-lowering drug 
(Benzafibrate) + 
garlic/drug only
900 mg/d, Control: 140.6 (18.7)/
137.2 (14.6)
Control: 82.4 (9.5)/
78.4 (9.2)
12 wks
Kiesewetter et al. 
1993, [15]
Parallel, Kwai, 32/32 Not reported Garlic: 84.7 (13.7)/
81.7 (12.1)
Garlic/placebo 800 mg/d, Control: 83.3 (11)/
81.7 (11)
12 wks,
Jain et al. 1993, [16] Parallel, Kwai, 20/22 Garlic: 129 (13)/130 
(17)
Garlic: 82 (6)/81 (10)
Garlic/placebo 900 mg/d, Control: 128 (10)/127 
(12)
Control: 83 (8)/82 (6)
12 wks
Saradeth et al. 1994, 
[17]
Parallel, Kwai, 25/27 Garlic: 125 (17)/127.4 
(16)
Garlic: 80.8 (8)/82.7 
(10)
Garlic/placebo 600 mg/d, Control: 124.6 (15.6)/
122.8 (12.5)
Control: 81.8 (9.4)/
81.1 (9.4)
15 wks
Simons et al. 1995, 
[18]
Crossover, Kwai, 28/28 Garlic: 127 (14)/119 
(7)
Garlic: 80 (8)/76 (5)
Garlic/placebo 900 mg/d, Control: 127 (14)/122 
(10)
Control: 80 (8)/76 (6)
12 wks
Steiner et al. 1996, 
[19]
Parallel study arm, Aged garlic extract, 41/41 Garlic: 134 (14)/126 
(14)
Garlic: 84 (8.6)/82.3 
(9)
Garlic/placebo 2400 mg/d, Control: 134 (11)/
129.6 (12)
Control: 85 (7.4)/81.7 
(8)
23 wks
Adler & Holub 1997, 
[20]
Parallel, Kwai, 12/13/10/11 Garlic: 123.3 (14.5)/
118.5 (9.4)
Garlic: 83.2 (2.5)/80 
(2.2)
Garlic/garlic+fish oil/
fish oil/placebo
900 mg/d, Control: 118.3 (3.2)/
119.6 (3)
Control: 79.6 (2.2)/
80.9 (2)
12 wks
Zhang et al. 2000, [21] Parallel, Distilled garlic oil, 14/13 Garlic: 117 (8)/113.5 
(6.4)
Garlic: 72 (7)/68.2 
(9.4)
Garlic/placebo 12.3 mg/d, Control: 109 (9)/
109.9 (9.4)
Control: 64 (7)/62.8 
(5.4)
16 wks
SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; vs, versus; mm Hg, millimetre mercury; mg/d, milligram per day; 
wks, weeks; mths, months.BMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
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(details on funding in Tables 2 and 3). Regression analy-
ses were conducted using Stata version 9 [51].
Plotting of blood pressure changes over time
We integrated additional blood pressure data from studies
included in the systematic review in BP/time plots for vis-
ual assessment of BP trends depending on BP at start of
treatment (mean/median SBP at start ≥ or < 130 mm Hg,
mean/median DBP ≥ or < 85 mm Hg). We included in the
plots data of placebo and non-placebo controlled trials
using garlic-only preparations, and reporting mean or
median SBP and/or DBP.
Results
Eleven of 25 studies included in our systematic review and
investigating the effect of garlic on blood pressure met the
inclusion criteria for meta-analysis (Table 1) [11-21].
Fourteen studies were excluded from meta-analysis: six
had no placebo control group [24,25,28,32,34,35],
another six reported incomplete data for mean SBP, DBP
or SD [23,26,27,30,31,33], and another two because they
used garlic combination supplements containing other
potentially hypotensive agents [22,29] (Additional File
1). We were able to contact the authors of four studies
with suitable study design but incompletely reported data
required for meta-analysis [20,26,27,33], and obtained
complete data from one study [20].
Ten of the eleven studies included in the meta-analysis
reported complete SBP and SD data required for meta-
analysis, and eleven studies reported DBP and SD data
(Table 1) (DBP data only [15]). Nine studies compared
garlic preparations to placebo, and two studies compared
the effect of garlic on blood pressure in addition to a drug
compared to drug plus placebo [11: diuretic, antihyper-
tensive, acts on sodium chloride reabsorption, 14: lipid-
lowering drug]. Nine studies used garlic powder (mainly
"Kwai", a standardised garlic supplement [52]), one study
used aged garlic extract [19] and another used distilled
garlic oil [21]. Dosage of garlic powder ranged between
600 and 900 mg per day, and duration of intervention
ranged from 12 to 23 weeks. A total of 252 individuals
allocated to a garlic intervention group and 251 individu-
als allocated to a control group were included in the meta-
analysis on SBP, and 283 (garlic) versus 282 (control) on
DBP. Mean blood pressure at start of intervention varied
markedly, with four studies reporting mean SBP in the
hypertensive range (≥140 mm Hg) and three studies
reporting mean DBP in the hypertensive range ≥90 mm
Hg) before treatment.
Meta-analysis of ten studies of the effect of garlic on SBP
showed a significant difference between garlic and control
groups, with garlic having a greater effect in reducing SBP
than placebo by 4.56 [95% CI (confidence interval), -
7.36, -1.77] mm Hg compared with placebo (p < 0.001)
(Figure 2a). Subgroup analysis of studies with mean SBP
in the hypertensive range at start of intervention revealed
a greater SBP reduction in the garlic group than placebo by
8.38 [95% CI, -11.13, -5.62] mm Hg (p < 0.001) (Figure
3a). Subgroup analysis of the remaining studies with
mean SBP in the normotensive range (<140 mm Hg) at
start of intervention showed no significant difference
between the garlic and placebo groups (Figure 3b).
Meta-analysis of eleven studies of the effect of garlic on
DBP did not show a significant difference between garlic
and placebo groups (-2.44 [95% CI, -4.97, 0.09] mm Hg,
p = 0.06) (Figure 2b). However, subgroup analysis of
studies with mean DBP in the hypertensive range at the
start of treatment revealed a significant difference between
garlic and control groups. The results indicate that garlic
was more effective in reducing DBP than placebo in
hypertensive individuals by 7.27 [95% CI, -8.77, -5.76]
mm Hg (p < 0.001) (Figure 3c). In contrast, subgroup
meta-analysis of "normotensive" individuals was not sig-
nificant (Figure 3d).
Flow diagram of study selection for systematic review and  meta-analysis Figure 1
Flow diagram of study selection for systematic 
review and meta-analysis. Abbreviations: BP, blood pressure; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, 
standard deviation; RCT, randomised controlled trial
153 potentially relevant 
publications retrieved for 
abstracts assessment 
38 potentially relevant 
studies retrieved for detailed 
assessment of full articles 
25 studies included in 
systematic review 
11 RCTs included in  
meta-analysis 
• 10 with data on SBP 
• 11 with data on DBP 
14 studies excluded from meta-
analysis because: 
• 6 had no control/ true placebo group 
• 6 reported no or incomplete mean 
  SBP, DBP or SD  
• 2 used combination of potentially  
   hypotensive agents 
13 studies excluded because  
• no effect of garlic on BP reported  
115 studies excluded because  
• review article or title or abstract of 
primary study not related to clinical 
effects of garlic on BP (n=112) 
• in languages other than English or 
German (n= 3) BMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
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Heterogeneity was moderate for meta-analysis of SBP of
all ten studies (I2 = 57.1%). However, we found no heter-
ogeneity in the subgroup analysis of studies with hyper-
tensive individuals at start of intervention (I2 = 0%). The
same trend was observed for meta-analysis of DBP with I2
= 83.2% for pooled analysis of all ten studies and I2 = 0%
for subgroup analysis of studies with hypertensive sub-
jects at start of intervention.
Regression analysis was conducted to test whether hetero-
geneity between the studies could be explained by one or
more of the following continuous variables: dosage (only
studies using garlic powder were included, n = 8/9 (SBP/
DBP), range 600–900 mg/d), duration of intervention
(SBP/DBP: n = 10/11, range 12–23 wks), and SBP or DBP
at start of intervention (SBP/DBP: n = 10/11, range 175–
109 SBP/102-64 DBP). SBP or DBP at start of intervention
proved to be a significant predictor for heterogeneity
(SBP: R = -0.151, p = 0.03; DBP: R = -0.316, p = 0.02),
strengthening the results of subgroup meta-analysis.
None of the other variables tested showed a significant
association with blood pressure outcomes (data not
shown). Furthermore, regression analysis did not provide
any evidence to suggest that receipt of industry funding (n
= 3) was associated with blood pressure outcomes.
Funnel plots and Egger regression tests suggested no pub-
lication bias in the meta-analyses (Figure 4).
Figure 5 augments our systematic review, allowing a visual
comparison of BP changes in garlic-only intervention
arms of published randomised trials (Table 1 and Addi-
tional File 1). Blood pressure changes over time were plot-
ted by blood pressure at start of treatment using data from
20 out of the 25 studies identified in our systematic
review, which included placebo and non-placebo control-
led trials, using garlic-only preparations, and reporting
mean or median SBP and/or DBP (studies in meta-analy-
sis [11-21]; as well as garlic-only intervention arms
included in systematic review [24-28,32,33,35,53]). In
total, mean or median SBP data was available for 23 gar-
lic-only intervention arms and mean or median DBP data
for 24 garlic intervention arms. Studies of groups with
high blood pressure (mean SBP or DBP) at start of inter-
vention generally showed a downward trend of blood
pressure over time (Figure 5a and 5c). These included
studies of groups with high normal blood pressure, also
known as pre-hypertension (SBP≥130 mm Hg, DBP≥85
mm Hg). Blood pressure generally changed little for stud-
ies of groups with mean SBP lower than 130 mm Hg or
Table 2: Assessment of study quality for studies included in meta-analysis
Study ID Randomisation Blinding Outcome measure: 
Blood pressure
Loss of follow up Funding source
Kandziora J 1988 (Study 1), 
[11]
+ ++ Primary, Mean of 2 
readings each standing + 
supine
Unclear -
Auer et al. 1990, [12] + ++ Primary, Mean standing + 
supine
Unclear -
Vorberg & Schneider 1990, 
[13]
+ ++ Primary, Mean standing + 
supine
G: 0%, C: 0% -
Holzgartner et al. 1992, 
[14]
+ ++ Secondary, Unclear G: 4.8%; C: 4.8%; T: 4.8% -
Kiesewetter et al. 1993, 
[15]
+ ++ Primary, Riva Rocci 
method
G: 20%; C: 20%; T: 20% -
Jain et al. 1993, [16] + ++ Primary, Mean of 2 
readings after 10 min rest; 
standard technique (JNC 
1988)
Unclear Industry grant
Saradeth et al. 1994, [17] + ++ Primary, Riva Rocci 
method
G: 2.8%; C: 8.3%; T: 5.6% -
Simons et al. 1995, [18] + ++ Primary, Mean of 2 
readings after 5 min rest, 
phase V diastolic BP
T: 9.7% Industry grant
Steiner et al. 1996, [19] 
parallel arm
+ ++ Primary, Unclear, manual T: 21.2% -
Adler & Holub 1997, [20] + ++ Primary, Sitting digital T: 8% Heart & Stroke Foundation
Zhang et al. 2000, [21] + ++ Primary, Over 10–30 min 
until repeated low values 
were obtained, means of 3 
lowest pulse rates + 
associated BP values
G: 6.7%; C: 13.3%; T: 10% Industry grant
+: adequate; ++: double blinding; -: not providedBMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
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mean DBP lower than 85 mm Hg at start of intervention
(Figure 5b and 5d).
Discussion
Our meta-analysis suggests that garlic supplementation
exerts a hypotensive effect compared to placebo, in partic-
ular in individuals with high blood pressure (SBP ≥ 140
mm Hg, DBP ≥ 90 mm Hg). Meta-analysis of all studies
showed a mean decrease of 4.6 ± 2.8 mm Hg for SBP in
the garlic group compared to placebo (p = 0.001), while
the mean decrease in the hypertensive subgroup was 8.4 ±
2.8 mm Hg for SBP and 7.3 ± 1.5 mm Hg for DBP (p <
0.00001). Low heterogeneity in the subgroup analyses in
addition to regression analysis confirmed that starting
blood pressure was a significant predictor for treatment
effect of garlic on blood pressure.
Interestingly, garlic-only intervention arms of reviewed
studies which were not suitable for meta-analysis also
showed a trend for greater reduction in BP with higher
starting BP. These observed trends are in line with the
findings from our subgroup meta-analyses, supporting
the evidence for a hypotensive effect of garlic in individu-
als with high or high normal blood pressure.
Whilst data from two studies [26,27], included in a previ-
ous meta-analysis [41], were not available, our meta-anal-
ysis incorporates data from six additional recent studies
[15,17-21], allowing subgroup analysis and increasing
generalisability. Quality of studies included in the meta-
analysis was generally high, however, 20% loss to follow
up in two trials and non-reporting of drop out rates in
three trials might have biased the results in those studies.
Heterogeneity observed in the meta-analyses including all
studies could only partly be explained by starting BP,
while dosage and duration of treatment were not associ-
ated with BP outcome. The absence of an association
between dosage and blood pressure change may suggest
that the hypotensive effect of garlic is comparable for dos-
Table 3: Assessment of study quality for studies excluded from meta-analysis
Study ID Randomisation Blinding Outcome measure: 
Blood pressure
Loss of follow up Funding source
Lutomski 1984, [22] + ++ Primary, Unclear G: 13.7%; C: 25.5%; 
T: 20.4%
-
Barrie et al. 1987, [23] + ++ Primary, Mean bilateral Unclear Industry grant
Harenberg et al. 1988, 
[24]
No (simple 
intervention)
Open label Primary, Unclear None -
Kandziora J. 1988 
(Study 2), [25]
+ + Observer blinded Primary, Mean of 2 
readings each standing + 
supine
Unclear -
Kiesewetter et al. 
1991, [26]
Unclear ++ Unclear Unclear -
DeASantos & 
Gruenwald 1993, [27]
+ ++ Primary, Unclear G: 16.7%; C: 10%; T: 
13.3%
Industry grant
DeASantos & Johns 
1995, [28]
+ Open label Primary, Average of 3 
readings
G: 10%; C: 15%; T: 
12.5%
-
Czerny & 
Samochowiek 1996, 
[29]
+ ++ Primary, Unclear (after 15 
min exercise)
Unclear -
Mansell et al. 1996, 
[30]
+ Unclear Primary, Unclear Unclear -
Steiner et al. 1996, 
[19] crossover arm
+ ++ Primary, Unclear, manual T: 21.2% -
McCrindle et al. 1998, 
[31]
+ ++ Primary, Unclear No drop-outs -
Durak et al. 2004, 
[32]
No (hypertensive/
nomotensive)
Open label Unclear Unclear -
Turner et al. 2004, 
[33]
+ ++ Secondary, Mean of 2 
readings after 10 min rest
G: 6.1%; C: 5.9%; T: 
6.0%
Industry grant
Dhawan & Jain 2004, 
[34]
Unclear 
(hypertensives/
normotensives)
++ Primary, As per JNC VI 
recommendations 2× after 
10 min rest DBP 
determined as Korotkoff 
phase V
No drop-outs Council of Medical 
Research grant
Jabbari et al. 2005, 
[35]
+ Open Primary, Unclear G: 12%; C: 12%; T: 
12%
-
+: adequate; ++: double blinding; -: not provided; JNC: Joint National CommitteeBMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
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ages between 600 and 900 mg per day of Kwai powder.
On the other hand, detection of an association between
duration of garlic intake and blood pressure change may
have been limited because the majority of studies (7 out
of 11) took final BP measurements at 12 weeks.
Our findings of the effect of garlic preparations on SBP/
DBP are comparable to the hypotensive effects of com-
monly-prescribed blood pressure drugs, e.g. beta-blockers
of 5 mm Hg for SBP, angiotension converting enzyme
inhibitors (ACEI) of 8 mm Hg for SBP [54], and angi-
otensin II type 1 receptor antagonists of 10.3 mm Hg for
DBP [55]. Our findings may have implications at a popu-
lation level, where a reduction of 4 to 5 mm Hg in SBP and
2 to 3 mm Hg in DBP has been estimated to reduce the
risk of cardiovascular morbidity and mortality by 8–20%
[56]. While our study focuses on the short-term effects of
garlic on blood pressure, larger scale long-term trials are
needed to test the effectiveness of garlic on cardiovascular
outcomes.
Most studies included in this review used garlic powder
dosages of 600–900 mg per day, providing potentially
3.6–5.4 mg of allicin, the active compound in garlic [36].
In comparison, fresh garlic cloves (~2 g) each yield 5–9
mg allicin [2]. However, different garlic preparations have
variable effectiveness on blood pressure, e.g. minimal
allicin compounds are found in aged garlic extract or heat
treated garlic, which may limit its hypotensive properties
[4,5]. Therefore it is advisable to use standardised garlic
preparations in future trials [57,58].
Supplementation with garlic preparations compared to
raw garlic provides the advantage of reducing or avoiding
Meta-analysis graphs on the effect of garlic on systolic blood pressure (A) or diastolic blood pressure (B) Figure 2
Meta-analysis graphs on the effect of garlic on systolic blood pressure (A) or diastolic blood pressure (B). Abbre-
viations: N, number of participants; SD, standard deviation; WMD, weighted mean difference; CI, confidence interval; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; s1, study 1 [ref 11].
A) SBP all studies 
B) DBP all studies 
Study Treatment Control WMD (random) Weight WMD (random)
N Mean Difference (SD) N Mean  Difference (SD) 95% CI % 95% CI
Kandziora-s1 1988       -10.00 [-14.30, -5.70]     
Auer 1990            -11.00 [-20.09, -1.91]     
Vorberg 1990         -9.00 [-14.85, -3.15]     
Holzgartner 1992     -4.60 [-9.84, 0.64]       
Jain 1993            2.00 [-4.66, 8.66]       
Saradeth 1994        4.20 [-2.58, 10.98]      
Simons 1995          -3.00 [-8.46, 2.46]       
Steiner 1996         -3.60 [-8.05, 0.85]       
Adler 1997           -6.10 [-13.84, 1.64]      
Zhang 2000          
20    -16.00(7.85)          20     -6.00(5.89)     
24    -19.00(16.58)         23     -8.00(15.20)    
20     -6.00(10.94)         20      3.00(7.63)     
47     -8.00(12.02)         47     -3.40(13.84)    
20      1.00(12.55)         22     -1.00(9.00)     
25      2.40(13.23)         27     -1.80(11.58)    
28     -8.00(10.57)         28     -5.00(10.28)    
41     -8.00(11.20)         41     -4.40(9.25)     
12     -4.80(10.64)         11      1.30(8.23)     
14     -3.50(5.94)          13      0.90(7.36)      -4.40 [-9.47, 0.67]       
Total (95% CI) 251                         252
Test for heterogeneity: Chi² = 20.99, df = 9 (P = 0.01), I² = 57.1%
Test for overall effect: Z = 3.20 (P = 0.001)
-10 -5 0 5 10
Favours treatment Favours control
-20 -15
12.70
6.22
10.12
11.09
8.94
8.78
10.73
12.45
7.59
11.37
100.00 -4.56 [-7.36, -1.77]
Study Treatment Control WMD (random) Weight WMD (random)
N Mean Difference (SD) N Mean  Difference (SD) 95% CI % 95% CI
Kandziora-s1 1988       -10.00 [-14.30, -5.70]     
Auer 1990            -11.00 [-20.09, -1.91]     
Vorberg 1990         -9.00 [-14.85, -3.15]     
Holzgartner 1992     -4.60 [-9.84, 0.64]       
Jain 1993            2.00 [-4.66, 8.66]       
Saradeth 1994        4.20 [-2.58, 10.98]      
Simons 1995          -3.00 [-8.46, 2.46]       
Steiner 1996         -3.60 [-8.05, 0.85]       
Adler 1997           -6.10 [-13.84, 1.64]      
Zhang 2000          
20    -16.00(7.85)          20     -6.00(5.89)     
24    -19.00(16.58)         23     -8.00(15.20)    
20     -6.00(10.94)         20      3.00(7.63)     
47     -8.00(12.02)         47     -3.40(13.84)    
20      1.00(12.55)         22     -1.00(9.00)     
25      2.40(13.23)         27     -1.80(11.58)    
28     -8.00(10.57)         28     -5.00(10.28)    
41     -8.00(11.20)         41     -4.40(9.25)     
12     -4.80(10.64)         11      1.30(8.23)     
14     -3.50(5.94)          13      0.90(7.36)     
20    -16.00(7.85)          20     -6.00(5.89)     
24    -19.00(16.58)         23     -8.00(15.20)    
20     -6.00(10.94)         20      3.00(7.63)     
47     -8.00(12.02)         47     -3.40(13.84)    
20      1.00(12.55)         22     -1.00(9.00)     
25      2.40(13.23)         27     -1.80(11.58)    
28     -8.00(10.57)         28     -5.00(10.28)    
41     -8.00(11.20)         41     -4.40(9.25)     
12     -4.80(10.64)         11      1.30(8.23)     
14     -3.50(5.94)          13      0.90(7.36)      -4.40 [-9.47, 0.67]       
Total (95% CI) 251                         252
Test for heterogeneity: Chi² = 20.99, df = 9 (P = 0.01), I² = 57.1%
Test for overall effect: Z = 3.20 (P = 0.001)
-10 -5 -10 -5 0 5 10
Favours treatment Favours control
-20 -15
12.70
6.22
10.12
11.09
8.94
8.78
10.73
12.45
7.59
11.37
100.00 -4.56 [-7.36, -1.77]
Study Treatment Control WMD (random) Weight WMD (random)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(2.95)          20     -8.00(3.69)      10.66 -8.00 [-10.07, -5.93]     
Auer 1990            24    -13.00(10.52)         23     -4.00(9.65)      7.18 -9.00 [-14.77, -3.23]     
Vorberg 1990         20     -4.00(3.05)          20      2.00(4.49)      10.42 -6.00 [-8.38, -3.62]      
Holzgartner 1992     47     -4.20(8.00)          47     -4.00(7.49)      9.76 -0.20 [-3.33, 2.93]       
Jain 1993            20     -1.00(7.38)          22     -1.00(5.89)      8.85 0.00 [-4.06, 4.06]       
Kiesewetter 1993     32     -3.00(10.42)         32     -1.60(8.80)      8.19 -1.40 [-6.13, 3.33]       
Saradeth 1994        25      1.90(7.43)          27     -0.70(7.48)      8.86 2.60 [-1.46, 6.66]       
Simons 1995          28     -4.00(5.88)          28     -4.00(5.89)      9.81 0.00 [-3.08, 3.08]       
Steiner 1996         41     -1.70(7.05)          41     -3.30(6.18)      10.00 1.60 [-1.27, 4.47]       
Adler 1997           12     -3.20(6.60)          11      1.30(5.60)      7.93 -4.50 [-9.49, 0.49]       
Zhang 2000           14     -3.80(6.92)          13     -1.20(5.17)      8.33 -2.60 [-7.19, 1.99]       
Total (95% CI) 283                         284 100.00 -2.44 [-4.97, 0.08]
Test for heterogeneity: Chi² = 59.38, df = 10 (P < 0.00001), I² = 83.2%
Test for overall effect: Z = 1.90 (P = 0.06)
-10 -5 0 5 10
Favours treatment Favours control
Mean Difference (SD) Mean Difference (SD)
Study Treatment Control WMD (random) Weight WMD (random)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(2.95)          20     -8.00(3.69)      10.66 -8.00 [-10.07, -5.93]     
Auer 1990            24    -13.00(10.52)         23     -4.00(9.65)      7.18 -9.00 [-14.77, -3.23]     
Vorberg 1990         20     -4.00(3.05)          20      2.00(4.49)      10.42 -6.00 [-8.38, -3.62]      
Holzgartner 1992     47     -4.20(8.00)          47     -4.00(7.49)      9.76 -0.20 [-3.33, 2.93]       
Jain 1993            20     -1.00(7.38)          22     -1.00(5.89)      8.85 0.00 [-4.06, 4.06]       
Kiesewetter 1993     32     -3.00(10.42)         32     -1.60(8.80)      8.19 -1.40 [-6.13, 3.33]       
Saradeth 1994        25      1.90(7.43)          27     -0.70(7.48)      8.86 2.60 [-1.46, 6.66]       
Simons 1995          28     -4.00(5.88)          28     -4.00(5.89)      9.81 0.00 [-3.08, 3.08]       
Steiner 1996         41     -1.70(7.05)          41     -3.30(6.18)      10.00 1.60 [-1.27, 4.47]       
Adler 1997           12     -3.20(6.60)          11      1.30(5.60)      7.93 -4.50 [-9.49, 0.49]       
Zhang 2000           14     -3.80(6.92)          13     -1.20(5.17)      8.33 -2.60 [-7.19, 1.99]       
Total (95% CI) 283                         284 100.00 -2.44 [-4.97, 0.08]
Test for heterogeneity: Chi² = 59.38, df = 10 (P < 0.00001), I² = 83.2%
Test for overall effect: Z = 1.90 (P = 0.06)
-10 -5 0 5 10
Favours treatment Favours control
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Subgroup meta-analysis on the effect of garlic on systolic blood pressure of hypertensive subjects (≥140 mm Hg at start of  intervention) (A) or 'normotensive' subjects (<140 mm Hg at start of intervention) (B); on diastolic blood pressure of hyper- tensive subjects (≥90 mm Hg) (C) or normotensive subjects (<90 mm Hg) (D) Figure 3
Subgroup meta-analysis on the effect of garlic on systolic blood pressure of hypertensive subjects (≥140 mm 
Hg at start of intervention) (A) or 'normotensive' subjects (<140 mm Hg at start of intervention) (B); on 
diastolic blood pressure of hypertensive subjects (≥90 mm Hg) (C) or normotensive subjects (<90 mm Hg) (D). 
For abbreviations see Fig 2.
A) SBP hypertensive subgroup 
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(7.85)          20     -6.00(5.89)      41.00 -10.00 [-14.30, -5.70]     
Auer 1990            24    -19.00(16.58)         23     -8.00(15.20)     9.18 -11.00 [-20.09, -1.91]     
Vorberg 1990         20     -6.00(10.94)         20      3.00(7.63)      22.20 -9.00 [-14.85, -3.15]     
Holzgartner 1992     47     -8.00(12.02)         47     -3.40(13.84)     27.62 -4.60 [-9.84, 0.64]       
Total (95% CI) 111                         110 100.00 -8.38 [-11.13, -5.62]
Test for heterogeneity: Chi² = 2.91, df = 3 (P = 0.41), I² = 0%
Test for overall effect: Z = 5.96 (P < 0.00001)
-10 -5 0 5 10
Favours treatment Favours control
-20 -15
Mean Difference (SD) Mean Difference (SD)
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(7.85)          20     -6.00(5.89)      41.00 -10.00 [-14.30, -5.70]     
Auer 1990            24    -19.00(16.58)         23     -8.00(15.20)     9.18 -11.00 [-20.09, -1.91]     
Vorberg 1990         20     -6.00(10.94)         20      3.00(7.63)      22.20 -9.00 [-14.85, -3.15]     
Holzgartner 1992     47     -8.00(12.02)         47     -3.40(13.84)     27.62 -4.60 [-9.84, 0.64]       
Total (95% CI) 111                         110 100.00 -8.38 [-11.13, -5.62]
Test for heterogeneity: Chi² = 2.91, df = 3 (P = 0.41), I² = 0%
Test for overall effect: Z = 5.96 (P < 0.00001)
-10 -5 -10 -5 0 5 10
Favours treatment Favours control
-20 -15 -20 -15
Mean Difference (SD) Mean Difference (SD)
B) SBP normotensive subgroup 
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Jain 1993            20      1.00(12.55)         22     -1.00(9.00)      12.24 2.00 [-4.66, 8.66]       
Saradeth 1994        25      2.40(13.23)         27     -1.80(11.58)     11.82 4.20 [-2.58, 10.98]      
Simons 1995          28     -8.00(10.57)         28     -5.00(10.28)     18.22 -3.00 [-8.46, 2.46]       
Steiner 1996         41     -8.00(11.20)         41     -4.40(9.25)      27.49 -3.60 [-8.05, 0.85]       
Adler 1997           12     -4.80(10.64)         11      1.30(8.23)      9.07 -6.10 [-13.84, 1.64]      
Zhang 2000           14     -3.50(5.94)          13      0.90(7.36)      21.16 -4.40 [-9.47, 0.67]       
Total (95% CI) 140                         142 100.00 -2.28 [-4.61, 0.05]
Test for heterogeneity: Chi² = 7.11, df = 5 (P = 0.21), I² = 29.6%
Test for overall effect: Z = 1.92 (P = 0.06)
-10 -5 0 5 10
Favours treatment Favours control
-15
Mean Difference (SD) Mean Difference (SD)
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Jain 1993            20      1.00(12.55)         22     -1.00(9.00)      12.24 2.00 [-4.66, 8.66]       
Saradeth 1994        25      2.40(13.23)         27     -1.80(11.58)     11.82 4.20 [-2.58, 10.98]      
Simons 1995          28     -8.00(10.57)         28     -5.00(10.28)     18.22 -3.00 [-8.46, 2.46]       
Steiner 1996         41     -8.00(11.20)         41     -4.40(9.25)      27.49 -3.60 [-8.05, 0.85]       
Adler 1997           12     -4.80(10.64)         11      1.30(8.23)      9.07 -6.10 [-13.84, 1.64]      
Zhang 2000           14     -3.50(5.94)          13      0.90(7.36)      21.16 -4.40 [-9.47, 0.67]       
Total (95% CI) 140                         142 100.00 -2.28 [-4.61, 0.05]
Test for heterogeneity: Chi² = 7.11, df = 5 (P = 0.21), I² = 29.6%
Test for overall effect: Z = 1.92 (P = 0.06)
-10 -5 0 5 10
Favours treatment Favours control
-15
Mean Difference (SD) Mean Difference (SD)
C) DBP hypertensive subgroup 
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(2.95)          20     -8.00(3.69)      53.01 -8.00 [-10.07, -5.93]     
Auer 1990            24    -13.00(10.52)         23     -4.00(9.65)      6.83 -9.00 [-14.77, -3.23]     
Vorberg 1990         20     -4.00(3.05)          20      2.00(4.49)      40.16 -6.00 [-8.38, -3.62]      
Total (95% CI) 64                          63 100.00 -7.27 [-8.77, -5.76]
Test for heterogeneity: Chi² = 1.92, df = 2 (P = 0.38), I² = 0%
Test for overall effect: Z = 9.45 (P < 0.00001)
-10 -5 0 5 10
Favours treatment Favours control
-15
Mean Difference (SD) Mean Difference (SD)
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Kandziora-s1 1988       20    -16.00(2.95)          20     -8.00(3.69)      53.01 -8.00 [-10.07, -5.93]     
Auer 1990            24    -13.00(10.52)         23     -4.00(9.65)      6.83 -9.00 [-14.77, -3.23]     
Vorberg 1990         20     -4.00(3.05)          20      2.00(4.49)      40.16 -6.00 [-8.38, -3.62]      
Total (95% CI) 64                          63 100.00 -7.27 [-8.77, -5.76]
Test for heterogeneity: Chi² = 1.92, df = 2 (P = 0.38), I² = 0%
Test for overall effect: Z = 9.45 (P < 0.00001)
-10 -5 -10 -5 0 5 10
Favours treatment Favours control
-15
Mean Difference (SD) Mean Difference (SD)
D) DBP nomotensive subgroup 
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Holzgartner 1992     47     -4.20(8.00)          47     -4.00(7.49)      17.49 -0.20 [-3.33, 2.93]       
Jain 1993            20     -1.00(7.38)          22     -1.00(5.89)      10.40 0.00 [-4.06, 4.06]       
Kiesewetter 1993     32     -3.00(10.42)         32     -1.60(8.80)      7.69 -1.40 [-6.13, 3.33]       
Saradeth 1994        25      1.90(7.43)          27     -0.70(7.48)      10.44 2.60 [-1.46, 6.66]       
Simons 1995          28     -4.00(5.88)          28     -4.00(5.89)      18.07 0.00 [-3.08, 3.08]       
Steiner 1996         41     -1.70(7.05)          41     -3.30(6.18)      20.85 1.60 [-1.27, 4.47]       
Adler 1997           12     -3.20(6.60)          11      1.30(5.60)      6.90 -4.50 [-9.49, 0.49]       
Zhang 2000           14     -3.80(6.92)          13     -1.20(5.17)      8.16 -2.60 [-7.19, 1.99]       
Total (95% CI) 219                         221 100.00 -0.06 [-1.37, 1.25]
Test for heterogeneity: Chi² = 7.48, df = 7 (P = 0.38), I² = 6.4%
Test for overall effect: Z = 0.09 (P = 0.93)
-10 -5 0 5 10
Favours treatment Favours control
Mean Difference (SD) Mean Difference (SD)
Study Treatment Control WMD (fixed) Weight WMD (fixed)
N N 95% CI % 95% CI
Holzgartner 1992     47     -4.20(8.00)          47     -4.00(7.49)      17.49 -0.20 [-3.33, 2.93]       
Jain 1993            20     -1.00(7.38)          22     -1.00(5.89)      10.40 0.00 [-4.06, 4.06]       
Kiesewetter 1993     32     -3.00(10.42)         32     -1.60(8.80)      7.69 -1.40 [-6.13, 3.33]       
Saradeth 1994        25      1.90(7.43)          27     -0.70(7.48)      10.44 2.60 [-1.46, 6.66]       
Simons 1995          28     -4.00(5.88)          28     -4.00(5.89)      18.07 0.00 [-3.08, 3.08]       
Steiner 1996         41     -1.70(7.05)          41     -3.30(6.18)      20.85 1.60 [-1.27, 4.47]       
Adler 1997           12     -3.20(6.60)          11      1.30(5.60)      6.90 -4.50 [-9.49, 0.49]       
Zhang 2000           14     -3.80(6.92)          13     -1.20(5.17)      8.16 -2.60 [-7.19, 1.99]       
Total (95% CI) 219                         221 100.00 -0.06 [-1.37, 1.25]
Test for heterogeneity: Chi² = 7.48, df = 7 (P = 0.38), I² = 6.4%
Test for overall effect: Z = 0.09 (P = 0.93)
-10 -5 0 5 10
Favours treatment Favours control
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Funnel plots of studies included in meta-analysis on the effect of garlic on systolic blood pressure (A) and diastolic blood pres- sure (B) Figure 4
Funnel plots of studies included in meta-analysis on the effect of garlic on systolic blood pressure (A) and 
diastolic blood pressure (B). The vertical line of Begg's funnel plot represents the pooled mean effect size, the dotted lines 
the 95% confidence interval, p-values are derived from Egger's test. Abbreviations: SB, systolic blood pressure; DBP, diastolic blood 
pressure; SE, standard error; mm Hg, millimetre mercury.
A)  
P=0.56
0
1
2
3
4
5
S
E
 
o
f
 
c
h
a
n
g
e
 
i
n
 
m
e
a
n
 
S
B
P
-15 -10 -5 0 5
Change in mean SBP, mm Hg
P=0.56
0
1
2
3
4
5
S
E
 
o
f
 
c
h
a
n
g
e
 
i
n
 
m
e
a
n
 
S
B
P
-15 -10 -5 0 5
Change in mean SBP, mm Hg
B) 
0
1
2
3
S
E
 
o
f
 
c
h
a
n
g
e
 
i
n
 
m
e
a
n
 
D
B
P
-10 -5 0 5
Change in mean DBP, mmHg
P=0.25
0
1
2
3
S
E
 
o
f
 
c
h
a
n
g
e
 
i
n
 
m
e
a
n
 
D
B
P
-10 -5 0 5
Change in mean DBP, mmHg
P=0.25BMC Cardiovascular Disorders 2008, 8:13 http://www.biomedcentral.com/1471-2261/8/13
Page 10 of 12
(page number not for citation purposes)
garlic breath and body odour, and prevents possible
destruction of active compounds in the cooking process.
Since garlic generally has a high tolerability [36], supple-
mentation with garlic preparations may provide an
acceptable alternative or complementary treatment
option for hypertension.
Future research investigating a dose-response relationship
between standardised garlic preparations and blood pres-
sure would be warranted, as limited data are available
[59]. Moreover, future trials could investigate whether gar-
lic has a blood pressure reducing effect in pre-hyperten-
sive subjects (SBP 120–139 mmHg, DBP 80–90 mm Hg),
Mean BP against time for garlic-only intervention arm(s) of studies using subjects with SBP≥130 mm Hg at start of intervention  (A), SBP < 130 mm Hg (B), DBP≥85 mm Hg (C), DBP < 85 mm Hg (D) Figure 5
Mean BP against time for garlic-only intervention arm(s) of studies using subjects with SBP≥130 mm Hg at 
start of intervention (A), SBP < 130 mm Hg (B), DBP≥85 mm Hg (C), DBP < 85 mm Hg (D). The plot incorpo-
rates garlic-only intervention arms of studies included in the systematic review: study arms in meta-analysis are in red/orange 
and marked with *, others are in black/grey. Diamonds illustrate trials using garlic powder and circles illustrate other garlic 
preparations. Studies in legend boxes are sorted by baseline blood pressure. Abbreviations: K88_2 = Kandziora 1988 (Study 2) 
[25], garlic vs drug; K88_1*= Kandziora 1988 (Study 1) [11], garlic+drug vs placebo+drug; A90* = Auer et al. 1990 [12]; DJ95 = De 
A Santos & Johns 1995 [28]; D04hyp = Durak et al. 2004 [32], hypertensive study arm; DJ04hyp = Dhawan & Jain 2004 [37], hyper-
tensive study arm; VS90* = Vorberg & Schneider 1990 [13]; H92*= Holzgartner et al. 1992 [15]; DG93 = De A Santos & Grünwald 
1993 [27]; J05swall = Jabbari et al. 2005 [35], swallowing garlic study arm; J05chew = Jabbari et al. 2005 [35], chewing garlic study 
arm; H88 = Harenberg et al. 1988 [24]; S96para = Steiner et al. 1996 [19], parallel study arm ; DJ04norm = Dhawan & Jain 2004 
[34], normotensive study arm; S96cross = Steiner et al. 1996 [19], crossover study arm; J93 = Jain et al. 1993 [16]; S95 = Simons et 
al.1995 [18]; S94 = Saradeth et al. 1994 [17]; D04norm = Durak et al. 2004 [32], normotensive study arm ; Z00 = Zhang et al. 2000 
[21]; Ki91 = Kiesewetter 1991 [26]; T04 = Turner et al. 2004 [33], median BP.
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B) Mean SBP at start < 130 mm Hg
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which may help to forestall progression to hypertension
[1,60].
Conclusion
This systematic review and meta-analysis suggests that gar-
lic preparations are superior to placebo in reducing blood
pressure in individuals with hypertension. Future large
scale long-term trials are needed to investigate whether
standardised garlic preparations could provide a safe alter-
native or complementary treatment option for hyperten-
sion in clinical practice.
List of Abbreviations
BP: blood pressure; CI: confidence interval; DBP: diastolic
blood pressure; mg/d: milligram per day; mm Hg: milli-
metre mercury; RCT: randomised controlled trial; SBP:
systolic blood pressure; SD: standard deviation.
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